Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lm-ANXA2
- Development stage
- Preclinical
- Lead developer
- Johns Hopkins University
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intraperitoneal
01
Overview
Lm-ANXA2 is a live-attenuated, double-deleted (LADD) *Listeria monocytogenes* (ΔactA ΔinlB) bacterial vector engineered to express the human Annexin A2 (ANXA2) protein. Developed primarily for the treatment of pancreatic ductal adenocarcinoma (PDAC), it functions as a cancer vaccine designed to induce a tumor antigen-specific CD8+ T cell response. ANXA2 is a pro-metastatic protein overexpressed in PDAC and other cancers. Preclinical studies demonstrate that Lm-ANXA2 can reprogram the "cold" tumor microenvironment of PDAC, increasing the infiltration of interferon-gamma (IFNγ)-expressing T cells. It is often studied in sequential combination with immune checkpoint inhibitors, such as anti-PD-1 antibodies, to overcome the immunosuppressive environment of pancreatic tumors.
- Other names
- ANXA2-expressing Listeria-based immunotherapyANXA-2-expressing Listeria-based immunotherapyANXA 2-expressing Listeria-based immunotherapyLADD-ANXA2LADD-ANXA-2LADD-ANXA 2Listeria-ANXA2Listeria-ANXA-2Listeria-ANXA 2
02
Targets
ANXA2 (Annexin A2)
Beyond the preview
Go deeper on Lm-ANXA2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lm-ANXA2.